AKT3 (E17K)

AKT3 · Variant type: point · HGVS: p.E17K

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Capivasertib	96.6%	3.4%	96.48
2	Sunitinib	28.1%	71.9%	91.73
3	Erlotinib	25.8%	74.2%	99.75
4	Brigatinib	24.4%	75.6%	82.96
5	Repotrectinib	21.9%	78.1%	84.21
6	Cobimetinib	19.6%	80.4%	100.00
7	Darovasertib	15.1%	84.9%	96.99
8	Everolimus	14.9%	85.1%	100.00
9	Ruxolitinib	14.0%	86.0%	98.25
10	Gilteritinib	13.5%	86.5%	88.97
11	Tivozanib	12.4%	87.6%	92.42
12	Canertinib	12.3%	87.7%	96.49
13	Lazertinib	11.6%	88.4%	97.47
14	Cabozantinib	10.6%	89.4%	92.73
15	Palbociclib	10.5%	89.5%	98.75
16	Quizartinib	10.4%	89.6%	99.50
17	Pemigatinib	10.4%	89.6%	98.23
18	Crizotinib	9.9%	90.1%	91.39
19	Temsirolimus	9.6%	90.4%	100.00
20	Lapatinib	9.3%	90.7%	99.25
21	Tenalisib	9.3%	90.7%	97.98
22	Vandetanib	8.6%	91.4%	95.74
23	Ponatinib	8.3%	91.7%	78.23
24	Pirtobrutinib	8.3%	91.7%	99.49
25	Lenvatinib	8.0%	92.0%	97.74

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Capivasertib	96.6%	98.5%	-1.9%
Sunitinib	28.1%	9.6%	+18.5%
Erlotinib	25.8%	—	—
Brigatinib	24.4%	—	—
Repotrectinib	21.9%	—	—
Cobimetinib	19.6%	—	—
Darovasertib	15.1%	11.2%	+3.9%
Everolimus	14.9%	—	—
Ruxolitinib	14.0%	—	—
Gilteritinib	13.5%	—	—
Tivozanib	12.4%	—	—
Canertinib	12.3%	—	—
Lazertinib	11.6%	—	—
Cabozantinib	10.6%	—	—
Palbociclib	10.5%	—	—
Quizartinib	10.4%	—	—
Pemigatinib	10.4%	8.6%	+1.8%
Crizotinib	9.9%	—	—
Temsirolimus	9.6%	—	—
Lapatinib	9.3%	—	—
Tenalisib	9.3%	17.5%	-8.1%
Vandetanib	8.6%	—	—
Ponatinib	8.3%	21.2%	-12.9%
Pirtobrutinib	8.3%	—	—
Lenvatinib	8.0%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 17.3ms